<DOC>
	<DOCNO>NCT00109096</DOCNO>
	<brief_summary>The purpose study determine : - whether standard high dose pemetrexed give patient ovarian primary peritoneal cancer recur ; - safety side effect standard high dos pemetrexed give patient ovarian primary peritoneal cancer recur ; - whether standard high dose pemetrexed help patient ovarian primary peritoneal cancer recur .</brief_summary>
	<brief_title>Study Pemetrexed Treatment Patients With Ovarian Cancer Who Have Failed Prior Platinum-Based Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Patient must diagnose ovarian primary peritoneal cancer Patient must 1 2 prior platinumbased chemotherapeutic regimen . Patient must adequate health status . Patient compliance geographic proximity allow adequate follow require . Signed informed consent patient legal representative require . Patient pregnant breastfeeding Patient receive treatment within last 30 day drug receive regulatory approval indication time study entry . Patient previously participate another study investigate pemetrexed . Patient unable unwilling take folic acid , vitamin B12 supplementation , corticosteroid . Patient take nonsteroidal antiinflammatory drug around time administration study drug .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2007</verification_date>
</DOC>